Vildagliptin Prices Fall By Over 70% In India Post Patent Expiry

Novartis Sells Vildagliptin Brand To USV, Cipla Explores Talks

10 Dec 2019

Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla

Wrestlers — Gliptins Price War Set To Intensify • Source: Shutterstock

Novartis AG has cashed out on two of its four licensed brands for vildagliptin in India, after a patent on the drug expired 9 December. Prices of vildagliptin and its combination are expected to drop sharply hereon, with one firm Panacea Biotec Ltd.'s product debuting at a discount of over 70% to current prices.

Novartis markets vildagliptin, an oral anti-hyperglycemic agent, as Galvus and vildagliptin in combination with metformin hydrochloride as Galvus Met. It also has co-marketing agreements for these with Abbott Laboratories Inc., Cipla Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

16 May 2025

• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

15 May 2025

• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

15 May 2025

• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.